High-dose Spinraza inches closer to EU approval despite FDA setback
A high-dose version of Biogen’s Spinraza (nusinersen) could soon be available in Europe, after a panel recommended the formulation’s approval.…
17 Nov 2025
Medicxi unveils €500m fund for asset-centric biotechs
London-headquartered investment firm Medicxi has unveiled a €500m ($580m) fund to back innovative biotechs, set against a backdrop of growing concern at the state of the commercial landscape in Europe…
17 Nov 2025
FDA approves Sarepta’s updated Elevidys label for DMD
Sarepta has received US Food and Drug Administration (FDA) approval for updated prescribing information for Elevidys (delandistrogene moxeparvovec), an adeno-associated virus (AAV)-based gene transfer therapy, which addresses the specific genetic…
17 Nov 2025
Sofinnova closes €650m healthcare fund for early-stage ventures
Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed at supporting early-stage healthcare companies in the US and Europe, at €650m ($750m) above its initial target. The fund…
14 Nov 2025
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new long-lasting infectious disease drug technology to its pipeline. The big pharma company will pay $221.50 per…
14 Nov 2025
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
Eli Lilly and Novo Nordisk have rebutted claims that they have partnered with telehealth provider Mangoceuticals, sending the online company's shares back down after an initial rise. On 13 November,…
14 Nov 2025
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy
Kyowa Kirin’s bet on Kura Oncology appears to have paid off, as the companies have secured approval for their jointly developed drug, Komzifti (ziftomenib). Following the US Food and Drug…